5 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
Follow Primary Biliary Cholangitis: new trials by email Literature Review of Primary Biliary Cholangitis trials Research Report on Primary Biliary Cholangitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC Obeticholic acid, Bezafibrate 200 MG, OCA Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | Intercept Pharmaceuticals | 75 | 2019-10-02 | 2026-07-16 |
| A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA Baricitinib, Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | Eli Lilly and Company | 2 | 2019-03-28 | 2020-10-14 |
| Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis APD334 - Primary Biliary Cholangitis | Phase 2 | Terminated | Arena Pharmaceuticals | 2 | 2017-12-29 | 2022-03-24 |
| Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid E6011, Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | EA Pharma Co., Ltd. | 29 | 2017-05-29 | 2019-01-04 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis Cilofexor, Placebo to match cilofexor - Primary Biliary Cholangitis | Phase 2 | Terminated | Gilead Sciences | 71 | 2016-12-01 | 2020-09-22 |
Liver Cirrhosis, Biliary (5) · Fibrosis (1)
Bile Duct Diseases (5) · Biliary Tract Diseases (5) · Cholestasis (5) · Cholestasis, Intrahepatic (5) · Digestive System Diseases (5) · Liver Cirrhosis (5) · Liver Diseases (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Fibrosis (4)
Bezafibrate (1) · baricitinib (1) · cilofexor (1) · etrasimod (1) · obeticholic acid (1) · quetmolimab (1)
Arena Pharmaceuticals (1) · EA Pharma Co., Ltd. (1) · Eli Lilly and Company (1) · Gilead Sciences (1) · Intercept Pharmaceuticals (1)
United States (3) · Australia (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Canada (1) · Croatia (1) · Czechia (1) · Estonia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1) · Japan (1)
Arena CT.gov Administrator (1) · Lynda Szczech (1)
2016 (1)